Necrotizing enterocolitis of the newborn: Pathogenetic concepts in perspective

Pediatric and Developmental Pathology

Volumn 1, Issue 1, 1998, Pages 2-16

  Hsueh, Wei ^a   Caplan, Michael S ^a   Tan, XiaoDi ^a   MacKendrick, William ^a   Gonzalez Crussi, F ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; APAFANT; AZEPINE DERIVATIVE; BEPAFANT; CELL SURFACE RECEPTOR; FIBRINOGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; TRIAZOLE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ANOXIA; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ELEMENTAL DIET; HUMAN; INTESTINE; METABOLISM; MICROBIOLOGY; MOUSE; NECROSIS; NECROTIZING ENTEROCOLITIS; NEWBORN; PATHOLOGY; PHYSIOLOGY; RAT; REVIEW;

ANIMALS; ANIMALS, NEWBORN; ANOXIA; AZEPINES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ENTEROCOLITIS, NECROTIZING; FOOD, FORMULATED; HUMANS; INFANT, NEWBORN; INTESTINES; LIPOPOLYSACCHARIDES; MICE; NECROSIS; NF-KAPPA B; PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEINS; RATS; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; TRIAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031598504     PISSN: 10935266     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100249900002     Document Type: Review

References (114)

1. Uauy R, Fanaroff AA, Korones S, et al. Necrotizing enterocolitis in very low birthweight infants: Biodemographic and clinical correlates. J Pediatr 1991;119:630-638.
2. Hack M, Horbar J, Malloy M, et al. Very low birthweight outcomes of the National Institute of Child Health and Human Development neonatal network. Pediatrics 1991; 87:587-597.
3. Morecroft JA, Hamilton PA, Holmes SJK. Necrotizing enterocolitis - multisystem organ failure of the newborn? Acta Paediatr (Suppl) 1994;396:21-23.
4. Kliegman RM, Fanaroff AA. Medical progress: Necrotizing enterocolitis. N Engl J Med 1984;310:1093-1103.
5. Brown EG, Sweet AY. Neonatal necrotizing enterocolitis. Pediatr Clin North Am 1982;29:1149-1170.
6. Gupta SK, Burke G, Herson VC. Necrotizing enterocolitis: Laboratory indicators of surgical disease. J Pediatr Surg 1994;29:1472-1475.
7. Stoll J, Kanto WP Jr, Glass R, et al. Epidemiology of necrotizing enterocolitis: A case control study. J Pediatr 1980;96:447-451.
8. De Curtis M, Paone C, Vetrano G, et al. A case control study of necrotizing enterocolitis occurring over 8 years in a neonatal intensive care unit. Eur J Pediatr 1987;146: 398-400.
9. Rowe MI, Reblock KK, Kurkchubasche AG, et al. Necrotizing enterocolitis in the extremely low birth weight infant. J Pediatr Surg 1994;29:987-991.
10. Hollwarth ME. Necrotizing enterocolitis: An editorial. Acta Paediatr (Suppl) 1994;396:1.
11. Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis. Ann Surg 1978;187:1-7.
12. Walsh MC, Kliegman RM. Necrotizing enterocolitis: Treatment based on staging criteria. Pediatr Clin North Am 1986;33:179-201.
13. Benirschke K. Pathology of neonatal enterocolitis. In: Moore TD, ed. Necrotizing Enterocolitis in the Newborn Infant: Report of the 68th Ross Conference on Pediatric Research. Columbus, Ohio: Ross Laboratories, 1974;29-30.
14. DeSa DJ. The spectrum of ischemic bowel disease in the newborn. Perspect Pediatr Pathol 1976;3:273-309.
15. Polin RA, Pollack PF, Barlow B, et al. Necrotizing enterocolitis in full-term infants: A case-control study. J Pediatr 1976;89:460-462.
16. Ballance WA, Dahms BB, Shenker N, et al. Pathology of neonatal necrotizing enterocolitis: A ten-year experience. J Pediatr 1990;117:S6-S13.
17. Nowicki P. Intestinal ischemia and necrotizing enterocolitis. J Pediatr 1990;117:S14-S19.
18. Lloyd JR. The etiology of gastrointestinal perforations in the newborn. J Pediatr Surg 1969;4:77-84.
19. Kliegman RM, Hack M, Jones P, Fanaroff AA. Epidemiologic study of necrotizing enterocolitis among low-birth-weight infants. J Pediatr 1982;100:440-444.
20. Ross G. Escape of mesenteric vessels from adrenergic and nonadrenergic vasoconstriction. Am J Physiol 1971;221: 1217-1222.
21. Bailey RW, Hamilton SR, Morris JB, et al. Pathogenesis of nonocclusive ischemic colitis. Ann Surg 1986;203:590-599.
22. Crissinger KD, Kvietys PR, Granger DN. Developmental intestinal vascular responses to venous pressure elevation. Am J Physiol 1981;130:537-542.
23. Kosloske AM. A unifying hypothesis for pathogenesis of necrotizing enterocolitis. J Pediatr 1990;117:S68-S74.
24. Carbonaro CA, Clark DA, Elseviers D. A bacterial pathogenicity determinant associated with necrotizing enterocolitis. Microb Pathog 1988;5:427-436.
25. Gupta S, Morris JG, Panigrahi P, et al. Endemic enterocolitis: Lack of association with a specific infectious agent. Pediatr Infect Dis J 1994;13:728-734.
26. Kliegman RM, Fanaroff AA, Izant R. Clostridia as pathogens in necrotizing enterocolitis. J Pediatr 1979;95:287-289.
27. Mollitt DL, Tepas JJ, Talbert JL. The role of coagulase negative staphylococcus in neonatal necrotizing enterocolitis. J Pediatr Surg 1988;23:60-63.
28. Rotbart HA, Nelson WL, Glode MP, et al. Neonatal rotavirus-associated necrotizing enterocolitis: Case control study and prospective surveillance during an out-break. J Pediatr 1988;112:87-93.
29. Joshi W, Winston YE, Kay S. Neonatal necrotizing enterocolitis: Histologic evidence of healing. Am J Dis Child 1973;126:113-116.
30. Hsueh W, Gonzalez-Crussi F, Arroyave JL. Platelet-activating factor: An endogenous mediator for bowel necrosis in endotoxemia. FASEB J 1987;1:403-405.
31. Gonzalez-Crussi F, Hsueh W. Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin. Am J Pathol 1983;112:127-135.
32. Hsueh W, Gonzalez-Crussi F, Arroyave JL. Platelet-activating factor-induced ischemic bowel necrosis. An investigation of secondary mediators in its pathogenesis. Am J Pathol 1986;122:231-239.
33. Sun XM, Hsueh W. Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor. J Clin Invest 1988;81:1328-1331.
34. Brown EG, Ainbender E, Henley WL, Hodes HL. Etiologic role of bacteria and intestinal function. In: Brown EG, Sweet AY, eds. Neonatal Necrotizing Enterocolitis. New York: Grune & Stratton, 1980;69-100.
35. Feuerstein G, Hallenbeck JM. Prostaglandins, leukotrienes, and platelet-activating factor in shock. Annu Rev Pharmacol Toxicol 1987;27:301-313.
36. Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991;115:457-469.
37. Benveniste J. Paf-acether, an ether phospho-lipid with biological activity. Prog Clin Biol Res 1988;282:73-85.
38. Hanahan DJ. Platelet activating factor: A biologically active phosphoglyceride. Annu Rev Biochem 1986;55:483-509.
39. Handley DA. Platelet-activating factor as a mediator of endotoxin-related diseases. In: Handley DA, Saunders RN, Houlihan WJ, Tomesch JC, eds. Platelet-Activating Factor in Endotoxin and Immune Diseases. New York and Basel: Marcel Dekker, 1990;451-495.
40. Toth PD. The biological effects of PAF antagonists on endotoxemia. In: Handley DA, Saunders RN, Houlihan WJ, Tomesch JC, eds. Platelet-Activating Factor in Endotoxin and Immune Diseases. New York and Basel: Marcel Dekker, 1990;589-608.
41. Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem 1988;57:505-518.
42. Zanetti G, Heumann D, Gerain J, et al. Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-alpha and to lipopolysaccharide. J Immunol 1992;148:1890-1897.
43. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-474.
44. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987;330:662-664.
45. Snyder F. Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. Am J Physiol 1990;259:C697-C708.
46. Denizot Y, Dassa E, Benveniste J, et al. Paf-acether production by Escherichia coli. Biochem Biophys Res Commun 1989;161:939-943.
47. Sanchez-Crespo M, Alonso F, Inarrea P, et al. Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: Evidence for a platelet independent mechanism. Immunopharmacology 1982;4: 173-185.
48. Hsueh W, Gonzalez Crussi F, Arroyave JL, et al. Platelet activating factor-induced ischemic bowel necrosis: The effect of PAF antagonists. Eur J Pharmacol 1986;123:79-83.
49. Stafforini DM, Elstad MR, McIntyre TM, et al. Human macrophages secret platelet-activating factor acetylhydrolase. J Biol Chem 1990;265:9682-9687.
50. Tarbet EB, Stafforini DM, Elstad MR, et al. Liver cells secrete the plasma form of platelet-activating factor acetylhydrolase. J Biol Chem 1991;266:16667-16673.
51. Tjoelker LW, Wilder C, Eberhardt C, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995;374:549-553.
52. Zhang C, Hsueh W, Caplan MS, Kelly A. Platelet activating factor-induced shock and intestinal necrosis in the rat: Role of endogenous platelet-activating factor and effect of saline infusion. Crit Care Med 1991;19:1067.
53. Schandene L, Vandenbussche P, Crusiaux A, et al. Differential effects of pentoxifylline on the production of tumour necrosis factor-alpha and interleukin-6 by monocytes and T cells. Immunology 1992;76:30-34.
54. Giroir BP, Johnson JH, Brown T, et al. The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest 1992;90:693-698.
55. Jaattela M. Biologic activities and mechanisms of action of tumor necrosis factor-α/cachectin. Lab Invest 1991;64: 724-742.
56. Vilcek J, Lee TH. Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem 1991;266:7313-7316.
57. Strieter RB, Kunkel SL, Bone RC. Role of tumor necrosis factor-α in disease states and inflammation. Crit Care Med 1993;21:S447-S463.
58. Camussi G, Bussolino F, Salvidio G, Baglioni C. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med 1987;166:1390-1404.
59. Valone FH, Epstein LB. Biphasic platelet-activating factor synthesis by human monocytes stimulated with IL-1-beta, tumor necrosis factor, or IFN-gamma. J Immunol 1988; 141:3945-3950.
60. Hsueh W, Sun X, Rioja LN, Gonzalez-Crussi F. The role of the complement system in shock and tissue injury induced by tumour necrosis factor and endotoxin. Immunology 1990;70:309-314.
61. Sun X, Hsueh W. Platelet-activating factor produces shock, in vivo complement activation, and tissue injury in mice. J Immunol 1991;147:509-514.
62. Huang L, Tan X, Crawford SE, Hsueh W. Platelet-activating factor and endotoxin induce tumour necrosis factor gene expression in rat intestine and liver. Immunology 1994;83:65-69.
63. Collart MA, Baeuerle P, Vassalli P. Regulation of tumor necrosis factor alpha transcription in macrophages: Involvement of four κB-like motifs and of constitutive and inducible forms of NF-κB. Mol Cell Biol 1990;10:1489-1506.
64. Baeuerle PA. The inducible transcription activator NF-κB: regulation by distinct protein subunits. Biochim Biophys Acta 1991;1072:63-80.
65. Tan X, Sun X, Gonzalez-Crussi FX, Gonzalez-Crussi F, Hsueh W. PAF and TNf increase the precursor of NF-kappa B p50 mRNA in mouse intestine: Quantitative analysis by competitive PCR. Biochim Biophys Acta 1994; 1215:157-162.
66. Deitch EA, Ma L, Ma WJ, et al. Inhibition of endotoxin-induced bacterial translocation in mice. J Clin Invest 1989;84:36-42.
67. Sun X, Caplan MS, Liu Y, Hsueh W. Endotoxin resistant mice are protected from PAF-induced shock, tissue injury and death. Roles of TNF, complement activation and endogenous PAF production. Dig Dis Sci 1995;40:495-502.
68. Sun X, MacKendrick W, Tien J, et al. Endogenous bacterial toxin is required for the injurious effect of PAF. Gastroenterology 1995;109:83-88.
69. Siren AL, Feuerstein G. Effects of PAF and BN 52021 on cardiac function and regional blood flow in conscious rats. Am J Physiol 1989;257:H25-H32.
70. Zhang C, Hsueh W. PAF-induced bowel necrosis. Effects of vasodilators. Dig Dis Sci 1991;36:634-640.
71. 4 by isolated, perfused rat small intestine in response to platelet-activating factor. J Clin Invest 1986;78: 108-114.
72. Hsueh W, Gonzalez-Crussi F, Arroyave JL. Sequential release of leukotrienes and norepinephrine in rat bowel after platelet-activating factor. A mechanistic study of platelet-activating factor-induced bowel necrosis. Gastroenterology 1988;94:1412-1418.
73. Cueva JP, Hsueh W. Role of oxygen derived free radicals in platelet activating factor induced bowel necrosis. Gut 1988;29:1207-1212.
74. Perdue MH, Ramage JK, Burget D, et al. Intestinal mucosal injury is associated with mast cell activation and leukotriene generation during Nippostrongylus-induced inflammation in the rat. Dig Dis Sci 1989;34:724-731.
75. Ninio E, Joly F, Hieblot C, et al. Bioxynthesis of pafacether. IX. Role for a phosphorylation-dependent activation of acetyltransferase in antigen-stimulated mouse mast cells. J Immunol 1987;139:154-160.
76. Zimmerman GA, Whatley RE, McIntyre TM, Prescott SM. Production of platelet-activating factor, a biologically active lipid, by vascular endothelial cells. Am Rev Respir Dis 1987;136:204-207.
77. Feinmark SJ. The role of the endothelial cell in leukotriene biosynthesis. Am Rev Respir Dis 1992;146:551-855.
78. Sun X, Qu X, Huang W, et al. The role of leukocyte beta 2-integrin in PAF-induced shock and intestinal injury. Am J Physiol 1996;270:G184-G190.
79. Kubes P, Suzuki M, Granger DN. Platelet-activating factor-induced microvascular dysfunction: Role of adherent leukocytes. Am J Physiol 1990;258:G158-G163.
80. Kubes P, Arfors KE, Granger DN. Platelet-activating factor-induced mucosal dysfunction: Role of oxidants and granulocytes. Am J Physiol 1991;260:G965-G971.
81. Sun X, Rozenfeld RA, Qu X, Huang W, Gonzalez-Crussi, Hsueh W. P-selectin-deficient mice are protected from PAF-induced shock, intestinal injury, and lethality. Am J Physiol 1997;273:G56-G61.
82. Keshav S, Lawson L, Chung LP, et al. Tumor necrosis factor mRNA localized to Paneth cells of normal murine intestinal epithelium by in situ hybridization. J Exp Med 1990;171:327-332.
83. Tan XD, Hsueh W, Gonzalez-Crussi F. Cellular localization of TNF-alpha transcripts in normal bowel and in necrotizing enterocolitis. TNF gene expression in Paneth cells, intestinal eosinophils and macrophages. Am J Pathol 1993;142:1858-1865.
84. 2 in the human gastrointestinal tract. Lab Invest 1995;72:201-208.
85. Tan XD, Wang H, Gonzalez-Crussi FX, Chang H, Gonzalez-Crussi, Hsueh W. Platelet-activating factor and endotoxin increase the enzyme activity and gene expression of type II phospholipase A2 in the rat intestine. J Immunol 1996;156:2985-2990.
86. Wiswell T, Robertson C, Jones T, et al. Necrotizing enterocolitis in full-term infants: A case-control study. Am J Dis Child 1988;142:532-535.
87. Leung M, Chau K, Hui P, et al. Necrotizing enterocolitis in neonates with symptomatic congential heart disease. J Pediatr 1988;113:1044-1046.
88. Hackett GA, Campbell S, Gamsu H, et al. Doppler studies in the growth retarded fetus and prediction of neonatal necrotizing enterocolitis, haemorrhage, and neonatal morbidity. Br Med J 1987;294:13-16.
89. Czyrko C, Del Pin CA, O'Neill JA, et al. Maternal cocaine abuse and necrotizing enterocolitis: outcome and survival. J Pediatr Surg 1991;26:414-421.
90. Hansbrough F, Priebe CJ, Falterman KW, et al. Pathogenesis of early necrotizing enterocolitis in the hypoxic neonatal dog. Am J Surg 1983;145:169-175.
91. Caplan MS, Sun X-M, Hsueh W. Hypoxia causes ischemic bowel necrosis in rats: The role of platelet-activating factor (PAF-acether). Gastroenterology 1990;99:979-986.
92. MacKendrick W, Caplan M. Necrotizing enterocolitis: New thoughts about pathogenesis and potential treatments. Pediatr Clin North Am 1993;40:1047-1059.
93. Musemeche CA, Kosloske AM, Bartow SA, et al. Comparative effects of ischemia, bacteria and substrate on the pathogenesis of intestinal necrosis. J Pediatr Surg 1986;21: 536-537.
94. Caplan M, Kelly A, Hsueh W. Endotoxin and hypoxia-induced intestinal necrosis in rats: The role of platelet activating factor. Pediatr Res 1992;31:428-434.
95. Moncada S, Higgs EA. The L-arginine-nitric oxide pathway. New Engl J Med 1993;329:2002-2012.
96. Caplan M, Hedlund E, Hill N, MacKendrick W. The role of endogenous nitric oxide and platelet-activating factor in hypoxia-induced intestinal injury in rats. Gastroenterology 1994;106:346-352.
97. MacKendrick W, Caplan M, Hsueh W. Endogenous nitric oxide protects against platelet-activating factor-induced bowel injury in the rat. Pediatr Res 1993;34:222-228.
98. Topalian SL, Ziegler MM. Necrotizing enterocolitis: A review of animal models. J Surg Res 1984;37:320-366.
99. Crissinger KD. Animal models of necrotizing enterocolitis. J Pediatr Gastroenterol Nutr 1995;20:17-22.
100. Barlow B, Santulli TV, Heird WC, et al. An experimental study of acute neonatal enterocolitis - the importance of breast milk. J Pediatr Surg 1974;9:587-594.
101. Pitt J, Barlow B, Heird WC. Protection against experimental necrotizing enterocolitis by maternal milk. I. Role of milk leukocytes. Pediatr Res 1977;11:906-909.
102. Barlow B, Santulli TV. Importance of multiple episodes of hypoxia or cold stress on the development of enterocolitis in an animal model. Surgery 1975;77:687-690.
103. Caplan MS, Hedlund E, Adler L, Hsueh W. Role of asphyxia and feeding in a neonatal rat model of necrotizing enterocolitis. Pediatr Pathol 1994;14:1017-1028.
104. Caplan MS, Hedlund E, Adler L, Lickerman M, Hsueh W. The platelet-activating factor receptor antagonists WEB 2170 prevents neonatal necrotizing enterocolitis. J Pediatr Gastroenterol Nutr 1997;24:296-301.
105. Hu W, McNicholl IK, Choy PC, Man RYK. Partial agonist effect of the platelet-activating factor receptor antagonists, WEB 2086 and WEB 2170, in the rat perfused heart. Br J Pharmacol 1993;110:645-650.
106. 2 enzymes: Regulation and physiological role. Biochem Pharmacol 1994;48:1-10.
107. 2 expression and pathogenesis of the sepsis syndrome. Circ Shock 1993;39:160-167.
108. Caplan MS, Sun X-M, Hsueh W, Hageman JR. Role of platelet activating factor and tumor necrosis factor-alpha in neonatal necrotizing enterocolitis. J Pediatr 1990;116: 960-964.
109. MacKendrick W, Hill N, Hsueh W, Caplan M. Increase in plasma platelet-activating factor levels in enterally fed preterm infants. Biol Neonate 1993;64:89-95.
110. Amer MD, Caplan MS. Neonatal necrotizing enterocolitis increases platelet activating factor levels in the stool of newborn infants. Clin Res 1994;42:372A.
111. Farr RS, Wardlow ML, Cox CP, et al. Human serum acid-labile factor is an acylhydrolase that inactivates platelet-activating factor. Federation Proc 1983;42:3120-3122.
112. Caplan M, Hsueh W, Kelly A, Donovan M. Serum PAF acetylhydrolase increases during neonatal maturation. Prostaglandins 1990;39:705-714.
113. Lucas A, Cole TJ. Breast milk and neonatal necrotizing enterocolitis. Lancet 1990;336:1519-1523.
114. Furukawa M, Lee EL, Johnston JM. Platelet-activating factor-induced ischemic bowel necrosis: The effect of platelet-activating factor acetylhydrolase. Pediatr Res 1993;34:237-241.